Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
April 1, 2019 Off

X4 Pharmaceuticals Provides Business and Clinical Development Update

By BusinessWire

Expects to commence the global Phase 3 pivotal trial of mavorixafor for the treatment of patients with Warts, Hypogammaglobulinemia, Infections…

April 1, 2019 Off

InVivo Therapeutics Reports 2018 Year-end Financial Results and Provides Business Update

By BusinessWire

CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the year ended December 31, 2018. Richard Toselli,…

April 1, 2019 Off

Teva’s AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults

By BusinessWire

In clinical trials, many patients on AJOVY experienced significant reductions of at least 50% in the number of monthly migraine…

April 1, 2019 Off

Turning Point Therapeutics’ Kinase Inhibitors Show High Potency against Targeted Oncogene Drivers and Their Mutations

By BusinessWire

Company Presents Four Studies at American Association for Cancer Research (AACR) Annual Conference Preclinical Data for Lead Asset Repotrectinib Continue…

April 1, 2019 Off

Recida Therapeutics Announces the Initiation of a Phase I Clinical Trial of RC-01, a Novel LpxC Inhibitor

By BusinessWire

RC-01 represents a new class of antibiotics in development for the treatment of serious antibiotic-resistant infections MENLO PARK, Calif.–(BUSINESS WIRE)–Recida…

April 1, 2019 Off

ADXS-PSA in Combination with KEYTRUDA® Prolonged Survival in Metastatic Castration-Resistant Prostate Cancer

By BusinessWire

Updated Results from Phase 1/2 Study to be Presented Today at the AACR Annual Meeting PRINCETON, N.J.–(BUSINESS WIRE)–Advaxis, Inc. (NASDAQ: ADXS),…

April 1, 2019 Off

Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe

By BusinessWire

LOS ANGELES & CASTRES, France–(BUSINESS WIRE)–Puma Biotechnology, Inc. (Nasdaq: PBYI) and Pierre Fabre have entered into an exclusive license agreement…

April 1, 2019 Off

Peloton Therapeutics Announces Clinical Data Update for PT2977 at European International Kidney Cancer Symposium

By BusinessWire

–Oral presentation highlights encouraging outcomes in patients with advanced renal cell carcinoma -Data supports continued clinical development with planned PT2977…

April 1, 2019 Off

PellePharm Initiates Pivotal Phase 3 Clinical Trial of Patidegib Topical Gel in Patients with Gorlin Syndrome

By BusinessWire

– Randomized, 12-Month, Pivotal Trial Evaluating the Safety and Efficacy of Patidegib Topical Gel to Reduce the Disease Burden of…

April 1, 2019 Off

Goldfinch Bio to Present at the 2019 Needham & Company 18th Annual Healthcare Conference

By BusinessWire

CAMBRIDGE, Mass.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/conference?src=hash" target="_blank"gt;#conferencelt;/agt;–Goldfinch Bio, a biotechnology company focused on discovering and developing precision medicines for the treatment of…

Posts pagination

Previous 1 … 3,315 3,316 3,317 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine